Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($9.23) EPS for the quarter, beating analysts’ consensus estimates of ($444.29) by $435.06, FiscalAI reports. The firm had revenue of $2.34 million during the quarter, compared to the consensus estimate of $4.85 million.
Jaguar Animal Health Stock Performance
Shares of NASDAQ:JAGX opened at $0.42 on Monday. Jaguar Animal Health has a 12-month low of $0.36 and a 12-month high of $1,039.50. The business has a 50 day moving average of $4.09 and a 200-day moving average of $101.51. The company has a quick ratio of 0.40, a current ratio of 0.69 and a debt-to-equity ratio of 0.35. The stock has a market cap of $816,660.00, a PE ratio of -0.00 and a beta of -0.09.
Analysts Set New Price Targets
JAGX has been the subject of a number of research analyst reports. Wall Street Zen upgraded Jaguar Animal Health to a “sell” rating in a report on Saturday, October 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.
View Our Latest Stock Report on JAGX
About Jaguar Animal Health
Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.
Featured Stories
- Five stocks we like better than Jaguar Animal Health
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
